<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841217</url>
  </required_header>
  <id_info>
    <org_study_id>UWA_PHR022009</org_study_id>
    <nct_id>NCT00841217</nct_id>
  </id_info>
  <brief_title>Regulation of Lipoprotein Transport in Metabolic Syndrome</brief_title>
  <official_title>Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable
      effect on lipoprotein metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metabolic syndrome (MetS) portends diabetes and cardiovascular disease (CVD).
      Dyslipoproteinaemia, reflected by elevated plasma triglyceride and reduced high-density
      lipoprotein (HDL) concentrations, is a cardinal feature of MetS that independently predicts
      CVD and is accordingly a therapeutic target for risk reduction. GW5015156 is a new PPAR-delta
      agonist that could be used to treat dyslipidemia in insulin resistance and obesity. However,
      the precise mechanisms of action of this agent on lipoprotein kinetics in MetS subjects have
      not yet fully been investigated. We therefore carried out a study to study the effect of
      GW5015156 on lipoprotein transport in subject with metabolic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ApoB transport rate</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ApoA and C-III transport rate</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity</condition>
  <condition>Lipid Disorders</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GW501516, 2.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW501516</intervention_name>
    <description>2.5mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any three of the following:

               -  Waist circumference &gt; 102 cm

               -  Triglycerides &gt; 150 mg/dL

               -  HDL-cholesterol &lt; 40 mg/dL

               -  Blood glucose &gt; 110 mhg/dL

               -  Blood pressures &gt; 130/85 mmHg

        Exclusion Criteria:

          -  Triglycerides &gt; 500 mg/dL

          -  Diabetes mellitus

          -  CVD

          -  Consumption of &gt; 30 g alcohol/day

          -  Use of agents affecting lipid metabolism

          -  APOE2/E2 genotype

          -  Creatinemia (&gt; 120 umol/L)

          -  Hypothyroidism

          -  Abnormal liver and muscle enzymes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Western Australia</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>February 10, 2009</last_update_submitted>
  <last_update_submitted_qc>February 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof P Hugh R Barrett</name_title>
    <organization>University of Western Australia</organization>
  </responsible_party>
  <keyword>Drug treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

